Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06557668
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-08
Brief Title:
Clinical Outcomes of Treatment With Immunomodulator Plus Cancer Therapies for Patients With Colorectal Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clinical Outcomes of Treatment With Immunomodulator Plus Standard Anti-cancer Therapies for Patients With Colorectal Cancer A Retrospective Study
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to evaluate the survival and treatment outcomes among colorectal cancer patients undergoing anti-cancer treatment both with and without an immunomodulator
Detailed Description:
Colorectal cancer CRC is the third most common cancer worldwide The clinical outcomes from CRC treatments are often unsatisfactory for the majority of patients The tumor microenvironment TME plays an important role to regulate tumor growth progression and metastasis and can limit the efficacy of cancer therapies Therefore targeting TME could provide an efficient approach for cancer treatment
Astragalus Polysaccharide Injection an immunomodulator which can stimulate medullary hematopoiesis and enhance immune function It also can modulate TME Astragalus Polysaccharide Injection has been approved as a prescription drug for alleviating cancer-related fatigue by the Taiwan Food and Drug Administration TFDA
In this retrospective study we will collect clinical data and survival status of colorectal cancer patients undergoing anti-cancer treatment from their medical records with and without immunomodulator Astragalus polysaccharide Injection It can be used to understand the possible clinical benefit of immunomodulator plus anti-cancer therapies for patients with colorectal cancer and physicians can refer to these results to give patients the suitable treatment recommendations
Astragalus Polysaccharide Injection an immunomodulator which can stimulate medullary hematopoiesis and enhance immune function It also can modulate TME Astragalus Polysaccharide Injection has been approved as a prescription drug for alleviating cancer-related fatigue by the Taiwan Food and Drug Administration TFDA
In this retrospective study we will collect clinical data and survival status of colorectal cancer patients undergoing anti-cancer treatment from their medical records with and without immunomodulator Astragalus polysaccharide Injection It can be used to understand the possible clinical benefit of immunomodulator plus anti-cancer therapies for patients with colorectal cancer and physicians can refer to these results to give patients the suitable treatment recommendations
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None